The Study to Evaluate the Safety and Efficacy of the Onyx Family
ConditionCoronary Artery Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age75-100
SponsorPusan National University Yangsan Hospital
About this trial
Observation of the safety and efficacy of 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using Onyx family stents in elderly patients aged 75 years or older
Eligibility criteria
Qualifiers
Aged 75 or more.
Eligible for interventional procedures.
Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%.
Able to take antiplatelets for at least 1 months after the procedure.
Disqualifiers
The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine [eg, rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled).
Patients with active pathologic bleeding.
Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia).
Trial design
Treatments tested in this trial
- Onyx family
Treatment groups
500 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov